Gender considerations along the HIV treatment cascade: An evidence review with priority actions

Melanie Croce-Galis

Jill Gay

Karen Hardee

Population Council

What Works Association

Population Council

Follow this and additional works at: https://knowledgecommons.popcouncil.org/departments_sbsr-rh

Part of the Demography, Population, and Ecology Commons, Family, Life Course, and Society Commons, International Public Health Commons, and the Women's Health Commons

Recommended Citation


This Brief is brought to you for free and open access by the Population Council.
Introduction

Evidence, including the recent findings of the START study, shows the overwhelming success of early HIV treatment in lowering the risk of developing AIDS as well as preventing HIV transmission. Access to antiretroviral therapy (ART) has improved significantly in recent years. At the end of 2013, there were 12.9 million people receiving ART, with 5.6 million of those added since 2010. Nonetheless, at the end of 2013 only 37% of people living with HIV were receiving treatment, leaving 22 million people in need of ART. In 2014, UNAIDS set the 90-90-90 target – an “ambitious but achievable” goal toward ending the AIDS epidemic by 2030 (see Box 1).

The 90-90-90 target focuses on equity; UNAIDS notes “it will be impossible to end the epidemic without bringing HIV treatment to all who need it.” This brief demonstrates how gender dynamics impact HIV treatment access and adherence and illustrates how greater attention to these dynamics within HIV interventions can improve treatment uptake and adherence critical to achieving the 90-90-90 goal. This brief uses WHO’s HIV care cascade as a useful framework within which to view the evidence regarding how gender dynamics help or hinder HIV treatment efforts (see Figure 1). This brief also identifies priority actions needed for gender-equitable treatment programming to achieve the 90-90-90 goal.

About this brief

This brief provides policymakers and program implementers with evidence about the impact of gender dynamics on treatment access and adherence and the gender-related gaps in treatment research and programming. It also includes priority actions that can be taken to better address gender within treatment programming and raises questions for implementation science in order to achieve the global 90-90-90 goals (see Box 1). This brief draws from What Works For Women and Girls: Evidence for HIV Interventions (www.whatworksforwomen.org) and uses the WHO treatment cascade framework to identify and analyze major gender considerations in providing antiretroviral therapy to those living with HIV in low- and middle-income countries. It focuses on antiretroviral treatment access and adherence as well as the gender dynamics related to who gets tested and under which circumstances. The brief does not cover the full provision of “HIV care” defined in the cascade to also include prevention, detection and treatment of co-infections such as TB, as well as nutrition and social support. For more on gender dynamics within those topics and to read about the full methodology for the evidence review, please see www.whatworksforwomen.org.
Gender Dynamics within the Care Cascade

Knowing One’s HIV Status

There are often gender differences in who gets tested and why. A review of the literature on studies conducted in rural India from 1980 to 2008 found that men sought testing because they were personally concerned, whereas women sought testing upon the recommendation of their antenatal provider—and in some cases reported mandatory testing by their provider. Most women access HIV testing within maternal health services. Since they come into contact with the health system regularly, pregnant women are disproportionately tested for HIV. A 2009 study in rural Mozambique found that HIV testing in non-pregnant women was “uncommon.” The emphasis on counseling and testing for prevention of maternal to child transmission (PMTCT) means that women who are not pregnant are inadequately reached with HIV testing and counseling services.

Women must navigate a number of hurdles in accessing testing. Many women, especially rural women, are unable to afford the time or money required to travel to a facility providing HIV testing. In some places, high rates of illiteracy mean that many women cannot access written information about the benefits or availability of HIV testing. Stigma, gender inequalities, and fear of negative outcomes following disclosure are significant barriers. Such outcomes include moral judgment and blame; ostracism by household or community; relationship termination; verbal and/or physical abuse as well as discrimination. In many countries, women living with HIV are spoken of as being promiscuous women who deserve this disease as a punishment for their sins. Fear of stigma and discrimination from health care providers is also a concern, especially for women from marginalized groups such as those who are sex workers or transgender.

Gender Norms Affect Men As Well as Women

Men, too, must overcome barriers to testing. A study in Lesotho found that there was better access to testing for women and a strong fear of testing among men. Global attention has focused often on prevention of vertical transmission, putting men simply in the role of supporting access to services for their female partners living with HIV, rather than caring for their own needs. In
many areas of the world, HIV is seen as a threat to a man’s masculinity, “requiring him to seek care, challenging his notions of fearlessness, and fueling fears of humiliation and that his wife will desert him.”

Men also may worry that they acquired HIV from extramarital partnerships and may therefore be less likely to disclose their HIV-positive serostatus to their spouse or to want to get tested in the first place.

A study in South Africa—where counseling and testing for HIV is most frequently accessed in antenatal care settings and a few stand-alone centers—found that men rarely initiate discussions with their female partners concerning HIV testing and mostly relied on female partners to test as a means of determining their own HIV status, not understanding that sexual partners who are serodiscordant can exist. Men also may worry that they acquired HIV from extramarital partnerships and may therefore be less likely to disclose their HIV-positive serostatus to their spouse or to want to get tested in the first place.

Addressing gender norms that suggest that ‘real men do not get sick’ will be critical to increasing HIV testing and counseling by men, as well as creating more opportunities for men to get HIV testing and counseling. Rapid expansion of testing, however, without ensuring informed consent and confidentiality could increase the risk of women and transgender people being rejected by their families, losing their property, and suffering violence and abuse. As noted by Jürgens and Cohen, “efforts to increase access to HIV testing must be accompanied by vastly scaled up efforts to confront the stigma and human rights abuses that deter people from seeking HIV tests in the first place.”

Priority Actions for Programming and Policy

■ Expand coverage to reach more women
  – Expand coverage of HIV testing and counseling both within and outside of antenatal care settings.

■ Link ART services with gender-based violence services
  – Strengthen referral programs for testing and ART services with services for gender-based violence.

■ Reach men
  – Promote campaigns that counter the harmful gender norm that “real men don’t get sick”; promote positive images of men using health services for the benefit of themselves, their partners, and their families.

■ Create programs to reach men as independent users of health services rather than exclusively through their female partners, both for testing and for treatment
  – Create testing programs for male clients of sex workers with linkage to treatment.

■ Strengthen couples testing
  – Revise national and local guidelines to include a context-appropriate definition of a “couple,” gender-sensitive ways to engage men and women in counseling, and linkages to available gender-based violence services, when needed.

■ Reach youth
  – Create opportunities for testing with linkage to treatment services in schools and universities in order to reach young men and young women prior to their first pregnancy.

Questions for Implementation Science

■ How can the number of men as users of health services – particularly for testing and treatment – be increased?
■ How can stigma be reduced to encourage greater uptake of HIV testing?
Enrollment in ART & Treatment Care*

Gender norms affect treatment access for men and women. Women constitute a higher proportion of those receiving ART than men. For all low- and middle-income countries, women constitute 51% of those eligible for care but make up 59% of those receiving ART. However, while more women than men have accessed treatment globally, structural factors and traditional gender norms can jeopardize women’s adherence, retention in care or ability to reduce transmission.

“Women are often more likely than men to attend health services because of dedicated provision of reproductive and child health clinics.” Many women are first tested and then put on treatment with the goal of prevention of vertical transmission. But inadequate attention is given to the treatment needs of women outside of this scope. The new WHO guideline recommending Option B+ allows pregnant women living with HIV to remain on treatment for life following their pregnancy. But the word “option” is a misnomer – it is an option for the country, not necessarily for the pregnant women. In a study in Malawi and Uganda, pregnant women were told they could have less than 24 hours to consider whether to go on treatment for life – a weighty decision. As one woman put it: “I’m 18 years, you are telling me drugs for life?” In addition, the focus has been on prevention of vertical transmission, or as one woman living with HIV states: “The doctors say, ‘Listen, we are not giving you these ARVs to save you, we are saving the baby…’” It is not surprising, therefore, that there are high dropout rates from treatment programs postpartum, including Option B+. In several countries, Option B+ rollout “has been characterized by high levels of ‘loss to follow up’ and lower rates of adherence.”

In addition, male involvement in Option B+ has been interpreted in some countries as a requirement that a man be present to access treatment. Some women instead choose to hire men to pose as their male partners: “Because when you go to antenatal you are asked to come with your partner, women have chosen to hire boda boda (motorcycle taxi drivers) to go with them to access the services.” Priority for treatment access to pregnant women creates problems within relationships: “Actually, the first time I was told about Option B+, the first question I remember I asked was ‘what about the man?’” Why did I ask this? Because I really saw that there were going to be conflicts of interest because men are going to now say, ‘Why women? Aren’t we also human beings?’” Or as another woman put it: “Men will say, ‘It’s me who made that woman pregnant. Why am I not started on treatment too?’”

Men Often Enroll in ART Later than Women

The Institute of Medicine notes that for PEPFAR data, each year there were more initial enrollments in ART among women than among men; the proportion has remained steady over time at about 65% of women and 35% of men. This imbalance is greater than the difference in HIV prevalence between men and women. Patient data from 307,110 adults from Kenya, Mozambique, Rwanda and Tanzania between 2006 and 2011 found that risk of late enrollment (CD4 counts under 350) was significantly higher for men and nonpregnant women as compared to pregnant women.

Harmful gender norms (e.g., viewing seeking health care as weakness) frequently cause men to delay presentation for treatment, which can reduce their life expectancy. A study of 4,775 patients from Uganda found there was a higher death rate for men, even when the analysis included women who accessed ART outside of ANC services, with more men presenting for care with lower CD4 counts, with single men having significantly lower CD4 counts than married men or single women.

“…Although women remain more vulnerable to HIV infection, once infected, men tend to be disadvantaged in...
terms of access to treatment and care.” In many countries, men initiate treatment later, are more likely to be lost to follow up, and have higher mortality rates. Focus group discussions with men in Uganda found that men found it difficult to seek treatment, which contradicted their assumed masculine autonomy and superiority.

A global review based on 36 studies in resource-rich and resource-limited settings found that being a heterosexual male was a consistent risk factor for presenting with low CD4 counts, resulting in less favorable outcomes for men once enrolled in treatment. In South Africa in 2011, the fraction of ART-eligible women who were receiving ART (65%) was significantly higher than the fraction of ART-eligible men who were on treatment (41%). An analysis of 23 cohort studies from Africa, including 216,008 participants found that only 35% of those accessing ART were men, despite an HIV prevalence of 40%, representing “a significant underrepresentation of men in ART programs.” In addition, the risk of death for men was 1.37 times higher than for women. However, men are seldom targeted as they are not often classified as vulnerable or marginalized. While this inequitable access for men to ART may be due, in part, to a focus on maternal health, equitable access to ART for men “should be conducted without …threatening HIV…treatment for women.”

A study of sex differentials in ART uptake in Zambia found that men were more likely to refuse ART even though men’s self-rated health was lower than women’s, with norms of masculinity presenting the biggest barrier for male uptake of ART. Other studies have found that men who received treatment were more likely to die than women because of late presentation for treatment or were frequently lost to follow up. A study of programmatic data on 334,557 adults enrolling in HIV care at 132 facilities in Kenya, Mozambique, Rwanda and Tanzania found that men were 1.6 times more likely to initiate ART with advanced HIV disease (CD4 count under 100) compared with women and that “this disparity seems to be widening…” A recent study found that men used their economic and decision-making power to informally access ART in order not to be seen at clinics, which are seen as a woman’s space. Out of shame, men suffered silently and attempted to cope by stealing their wives’ ARVs. The practice of men stealing ARVs from their wives endangers both partners, jeopardizing women’s adherence.

Gender norms of female submissiveness and women as caretakers may be critical also for the higher uptake of ARVs by women, as explained by one Vietnamese woman living with HIV: “Women have no choice but to take the drugs. Meanwhile, men are the ones who consider whether or not to take the drugs because they don’t need to think of anything else except themselves.” Greater attention needs to be paid to ensuring that men living with HIV know their serostatus, have access to condoms, understand the need for consistent and correct condom use, and have equitable access to treatment. “Closing the coverage gap in men needs to be a priority to tackle health-related gender inequalities, improve overall health in men, and decrease transmission…”

**Inequitable Access to ART Also Differs by Age and Social Status**

Some studies have found that equity in access differs by age group with inadequate treatment access for adolescent women. In Malawi, for example, of 10,000 people on treatment, proportionately more women accessed treatment than men. However, in the 15 to 19 year age group, more men were proportionately on treatment despite the fact that HIV prevalence in this age group was higher among women. “Despite the growing number of older children and adolescents who develop symptoms, there has been little focus on providing this group with specialized HIV care.” Providers need training to provide nonjudgmental care. Instead, one study found that providers would say to adolescents living with HIV: “You are HIV-positive. You are not expected to have sex. You are not expected to have a baby.”

Transgender people are marginalized and subject to stigma, violence and social exclusion, which can affect treatment access and adherence. Similarly, sex workers – who are, worldwide, mostly women and among the most marginalized of women – face barriers in accessing treatment due to stigma, discrimination and social exclusion. Importantly, WHO notes that key populations should have the same access to ART and care and the same ART management as other populations, “[h]owever, because of stigma, discrimination and marginalization, they frequently present late for treatment.” Thus, ART programming that respects human rights is critical for key populations, as for all.

**Priority Actions for Programming and Policy**

- **Strengthen services**
  - Ensure that all service providers are trained in the principles of non-discrimination to ensure that people of different gender identities can access quality services with respectful treatment, counseling and support.

† While transgender issues are raised throughout this brief, a full discussion of the barriers to treatment by sex workers, people who use drugs and other key populations is beyond the scope of this brief.
Identify avenues to provide treatment to women outside of antenatal care services to reach women who are not pregnant.

Reach men
Create both an inclusive atmosphere as well as physical space within clinics where men can initiate ART with follow up within communities and with male peer support.

Reach youth
Create services that will reach adolescent girls living with HIV, particularly those under age 18 who will not be reached through pediatric services yet are not comfortable in adult settings.

Create sustainable adolescent friendly HIV services that also meet reproductive health needs.

Review data
Analyze HMIS data on an ongoing basis to assess gender equitable access, adherence, and retention to ensure that care and treatment services are reaching people in proportion to the burden of the epidemic.

Questions for Implementation Science
- How can men’s engagement with health and ART services be fostered without interfering with women’s decision-making and autonomy?
- How can treatment programming reach those who have not yet been reached?

ART Retention
For the most part, men and women have similar ART adherence rates. But there are gender differences in predictors of adherence. Women may need family support, including redistribution of household responsibilities, to enable them to adhere to treatment. Even if drugs are free or subsidized, women may not be able to afford the time or money required to travel to a clinic. A qualitative study of women living with HIV in Colombia found that women prioritized the needs of their HIV-positive children over their own adherence needs. Women in Malawi and Uganda also reported financial and other challenges in managing their own adherence as well as that of their children. Some women sold their ARVs for economic survival. Women may also have difficulty navigating treatment when it conflicts with other activities for survival. Sex workers, in particular, face difficulties in adherence in large part due to stigma and discrimination. One South African sex worker points out the struggles she faces: “If you don’t pay off the police, they take you to jail…you can’t take antiretroviral drugs or any medication you need.”

Female sex workers in Vietnam reported that they were not allowed to join networks of people living with HIV who gained access to valuable support and information services because they were seen as “social evils” rather than “innocent wives getting the disease from their husband.”

Other Life Activities Affect Women’s Adherence
Pregnancy represents an additional sex-related factor in treatment. In a study of 4,531 women from numerous treatment sites in Sub-Saharan Africa, one-third experienced a pregnancy within four years of ART initiation. Yet few treatment programs are designed with the likelihood of pregnancy in mind. Most of the world’s women living with HIV are of reproductive age and will need either contraception or discussions on how to become pregnant while reducing the risk of HIV transmission to their infants and/or partners.

Side effects can also deter women from adhering to treatment plans. Some medications cause a redistribution of body fat resulting, for example, in a large belly, or a collection of fat at the base of the neck, or loss of fat from the cheeks. Women have reported problems with adherence due to how ARVs changed their appearance, with bodily changes creating visibility of their HIV-positive serostatus and consequent stigma. Women may also be more adversely affected by the common side effects of ARVs that result in anemia. A study of quality of life among people living with HIV in Cuba found that pain interfered more in women’s lives than in men’s lives, and that women did not enjoy the same health-related quality of life as men. In Vietnam, men, even if they injected drugs, reported better quality of life on antiretroviral therapy than did women, as women cared for the men.

Men’s Sense of Masculinity Can Affect Treatment Adherence
Men also face particular challenges in accessing and adhering to HIV treatment. Men’s ideal sense of masculinity may be threatened by “disclosing their HIV status and seeking treatment in fear that they would be perceived as failing sons, husbands or breadwinners.” A study of men in Uganda found that adherence challenged gender norms of masculinity, with men reporting that nurses scolded them: “It involves being shouted upon like a child, don’t you see, no respect at all.” Being physically strong, capable of hard work and having children were also seen as signs of masculine identity, which were threatened by being labeled HIV-positive. A study from South Africa found that men’s adherence was challenged by employment, with problems getting time away from work for clinic visits or loss of income due to waiting in clinic lines.
Treatment may be undertaken by some men to regain health and self-worth with the ability to work and provide for their families as a sign of their masculinity. In one South African study, when men were not yet on ART but diagnosed with HIV, family members withdrew support and care, as family members feared acquiring HIV. Once on ART and feeling physically well, men felt prepared to withstand potential rejection as well as confident to look for a girlfriend if a partner rejected them for their positive serostatus.

Support groups and counseling for men may also be beneficial and men do request them. Focus group discussions in South Africa with men living with HIV on treatment who had disclosed to their partners found that they wanted to access male-only support groups with guarantees that their HIV status would not be disclosed outside of the support group setting. Despite the fact that support groups were available four times per week, men did not know of these support groups, which met at clinics where they collect their medication. In Uganda, men who were recipients of financial support, such as expenses for children’s education or given livelihood options, such as goats, were more adherent than men without this support.

Stigma and Gender Norms Can Make Efforts to Encourage Retention and Reduce HIV Transmission Difficult

Non-judgmental, non-stigmatizing interventions both within the health sector and outside the health sector, such as transforming gender norms, reducing violence against women, revising laws that criminalize non-disclosure of HIV, to name a few, need to be implemented in order to support safer sexual behavior once someone knows his or her positive serostatus.

Some serodiscordant couples identify fear of transmission as a primary concern in their relationships or fear the impact that disclosure will have on the HIV-negative partner. A study in South Africa found that among 413 men living with HIV and 641 women living with HIV, stigma and discrimination was associated with non-disclosure and that non-disclosure was associated with HIV transmission risk behaviors.

“Persistent rates of nondisclosure by those diagnosed with HIV raise difficult ethical, public health and human rights questions about how to protect the medical confidentiality, health and well-being of people living with HIV on the one hand, and how to protect partners and children from HIV transmission on the other.”

Criminalization of transmission and nondisclosure undermines rights while serving little public health benefit, but gender issues are key to HIV disclosure. Because women are tested for HIV at much higher rates than men, any approach that blames women living with HIV for not disclosing their status will disproportionately burden women. Where male partners have been unwilling to get tested for HIV, some women living with HIV did not feel an obligation to disclose their positive serostatus. Women “reflected upon the fact that men seemed unwilling to test but preferred to blame their female partners.” In some cases, women are significantly less likely to know their partner’s status than men. And one study of women living with HIV in South Africa found that consistent condom use was not correlated with disclosure to either HIV-negative or HIV-positive male partners. For women living with HIV, “it is ultimately the decision of the man to either use a male condom or not,” with gender norms on sexuality key to male use of condoms. Some evaluated interventions exist regarding women’s use of female condoms in the absence of male condom use. However, “…limited access to female condoms and substantially higher costs have limited uptake and use of female condoms,” thus limiting an opportunity to reduce HIV infection through a woman-initiated prevention method.

Transgender people can face a double stigma for their gender as well as for their positive serostatus, making accessing needed health and HIV services, which usually operate on strict male/female gender identities, extremely difficult. They are often overlooked in HIV treatment programming.
Fear of Disclosure Impacts ART Retention and Transmission Reduction Efforts

Disclosure is not a one-time event but a process calling for careful consideration as to whom to disclose and when. A study in Zimbabwe of 200 women living with HIV on ART found that 96.5% disclosed to at least one person, most frequently their sister. Both women and men need to learn how to negotiate safe sex prior to disclosure, knowing when to disclose and how to disclose. Women in one study noted that once they disclosed, no man had stayed with them. In another study in Uganda, “the need to provide for children was a particularly strong motivation for women to avoid disclosure,” as men abandoned or abused partners who disclosed or requested condom use. One cross-sectional survey in Cameroon found that women living with HIV who were not financially dependent on their male partners were much more likely to have used condoms, suggesting the importance of the enabling environment.

A study in South Africa found that for men, disclosure undermined their sense of masculinity as health-seeking would portray them as weak and dependent, as well as subject to control by health care providers, noting that “men believed that ‘real men’ deal with personal problems on their own, instead of asking help from other people.” However, once on ART, men’s health and appearance improved and they felt publicly able to share their HIV-positive serostatus, which in turn won them support, approval and admiration, becoming role models for breaking the secrecy and stigma surrounding HIV. Other studies found that men were particularly critical of serodiscordant couple interventions, as couples counseling puts “the man on trial.” As one man put it: “It is as if you are before a court, as you know women can get authority over the man when other people are there...So your wife may ask you how the disease came about. So you have to reveal the extra affairs...” Providing sex-segregated counseling may be more effective.

Priority Actions for Programming and Policy

- Provide information and support
  - Within all treatment programs, counsel both men and women on their options if they want to become pregnant/have a child or avert unintended pregnancies.
  - Create sex-segregated ART support groups, similar to the mothers2mothers model for pregnant women, for all who are living with HIV.
  - Strengthen training for counselors and other healthcare workers providing guidance on safe disclosure for both men and women (separate guidance for each, address gender issues for each).
  - Provide services that are user-friendly such as with on-site childcare or at times or locations that are women- men- and family-friendly.

- Address legal barriers
  - Create or strengthen programs for the judicial sector to ensure ART is available within jails, prisons, etc. and that those living with HIV taken into custody can adhere to ART. (This is particularly important for sex workers).
  - Decriminalize HIV transmission, which can be particularly harmful to women and may criminalize vertical transmission during pregnancy.

- Analyze gender dynamics
  - Review and design programs to ensure that they are based upon a gender analysis and address harmful gender norms and gender-based violence and are evaluated to better elucidate how a gender-sensitive approach affects treatment adherence and retention.

Questions for Implementation Science

- How can peer support be effectively provided for men and how does it differ from a peer support model for women?

Viral Suppression

ART adherence is critical to achieving viral suppression. Additional factors such as drug resistance, drug interactions and biological differences may also be subject to gender-related challenges in achieving viral suppression.

Women may be at greater risk for viral drug resistance or transmitting drug resistant strains due to the temporary use of antiretrovirals to reduce vertical transmission. Further evaluation is needed to understand these risks. While it is
clear that those who go on ARV therapy for their own treatment needs should not interrupt treatment, treatment interruption for women who are on ART to prevent perinatal transmission rather than for their own health needs is the subject of an ongoing clinical trial (PROMISE), with results expected in 2017. “The risk for maternal health of stopping…maternal triple ARV prophylaxis after breastfeeding cessation is unknown” – especially if a woman living with HIV has multiple pregnancies. WHO recommendations for Option B+, i.e., lifelong treatment for pregnant women, may reduce stopping and re-starting ART which can carry increased risk for mortality and morbidity.

Monitoring drug interactions can be increasingly complex in populations that may also be using drugs for co-infections, co-morbidities, or recreationally. Cross-hormonal treatment protocols for transgender women and men may affect HIV treatment success. While there are currently no documented drug interactions among these medications and ARVs, further research is needed. It is possible that ART may lead to hormonal fluctuations and metabolic abnormalities among transgender women taking hormonal medications and close monitoring is needed.

**There May be Sex Differences in ART Efficacy**

Access to treatment by sex has been disaggregated in a number of studies. However, few studies have analyzed sex differences. Studies to date have not shown differences in virologic efficacy of ART by sex, although a number have suggested that sex may influence the frequency, presentation, and severity of selected ARV-related adverse events. One study found differences in virologic failure (i.e., ART fails to suppress and sustain viral load to less than 200 copies/mL) by sex, with women having an advantage over men. Another study found that women were more likely to have viral suppression and better ART outcomes while other research found that women were in better clinical condition than men. “Although data are limited, there is evidence that women may metabolize and respond to specific medications, including ARV drugs, differently than men.” In some studies, however, women experience more adverse drug reactions than men.

d’Arminio Monforte et al., 2013 notes “[a]lthough published data suggest that there are no significant differences in ART efficacy between women and men, it must be emphasized that this is a conclusion drawn from a limited evidence base.” ARVs are administered at fixed dosages that do not take into account the different body weight, etc. of each sex. A study in Tanzania in which 70% of the 234 patients were women found that after one year of standard ART, a higher proportion of females had an undetectable viral load but with less of a CD4 cell increase than men. Women started treatment at a less advanced disease stage but women lost their immunological advantage over men despite a better virological treatment response. In addition, men were better informed about the use of ART. Other studies have found that men are disadvantaged in ART due to differences in body weight compared to dose.

The potential role of sex differences in HIV disease progression and treatment response is an understudied area of inquiry, with women under-represented in clinical trials. A review of forty randomized controlled trials for 18 new drug applications for antiretroviral therapy submitted to the U.S. Food & Drug Administration (FDA) between...
2000 and 2008 found that only 20% of trial participants were women. Even when women are included, sex-specific analysis of the data is rarely undertaken. No studies have addressed the possible interactions between ART and sexual hormones in both men and women, including pre, peri or post-menopause. At a minimum, “research data should be disaggregated by sex to ensure opportunities for [sex- and] gender-based analysis.”

**Priority Actions for Implementation Science**

- Analyze gender and sex differences in clinical data
  - Enroll more women in clinical trials and conduct more gender analyses of the data in order to identify potential sex differences in antiretroviral efficacy and in ART impact on cardiovascular and other noncommunicable diseases affecting those living with HIV.
  - Carry out further research on the effect of ART on hormonal medications and vice versa.

**Above All, ART Programming Must Include Respect for Human Rights**

Expanding access to ART while considering equity and human rights is urgently needed. WHO’s 2013 guidelines note “human rights and ethical principles should guide… national treatment policies to ensure that they are equitable and meet the specific needs of all beneficiaries.” Requiring people living with HIV to disclose their serostatus to sexual partners and/or community members in order to receive treatment, care or support is a human rights violation. Similarly, coercing women to accept contraception in order to access treatment violates women’s rights to make their own fertility choices. While “treatment buddies” can be supportive, requiring a treatment buddy or medical companion to access ARV therapy may place undue burdens on women and their children: a study of 1,453 patients in Uganda on the impact of requiring patients to disclose their HIV status and have a “treatment buddy” or “medical companion” to access ARV therapy found that 41% of the women chose a child as their medical companion versus 14% of the men. Individuals with limited networks may delay enrolling in or may drop out of care when treatment support “buddies” are required.

**START is Just the Beginning: Moving Forward in Ensuring Gender-Equitable ART**

Given the myriad ways that gender norms impact antiretroviral treatment access and adherence, it is crucial that HIV treatment programming recognize and address gender issues in order to achieve the 90-90-90 goals which seek to increase the numbers of people who know their status, enroll and sustain ART treatment and achieve viral suppression. If gender dynamics are not addressed within treatment programming and policy, efforts to increase treatment coverage will be undermined.

Now that the Strategic Timing of Antiretroviral Treatment (START) study has shown substantially improved outcomes for early treatment initiation, Kavanagh et al. argue that states’ “core minimum obligations now include access to early ART for both individual and collective benefit. Governments can now reasonably be expected to enable early viral suppression through human rights-based interventions….” These efforts must take into consideration the issue of autonomy that women living with HIV have consistently raised with respect to healthcare decision-making, including whether and when to start treatment. “Despite potential individual and public health benefits for women living with HIV, the decision to begin treatment for HIV is a deeply personal decision that reflects a variety of private, contextual and structural factors.”

Although there is a growing understanding and documentation of how gender impacts HIV treatment, there remain few evaluated interventions demonstrating what works to overcome these gender-related barriers. A number of questions and concerns remain: how will access to ART be prioritized? How will treatment be financed? How can ART be equitably accessible? How will gender dynamics be addressed in ensuring access? Most importantly, how can ART availability and accessibility be partnered with informed consent about the risks and benefits of treatment so that all people living with HIV may decide for themselves how best to stay healthy and live full, productive lives?
The photographs in this material are used for illustrative purposes only; they do not imply any particular health status, attitudes, behaviors, or actions on the part of any person who appears in the photographs.


References

1. WHO 2015. Consolidated strategic information guidelines for HIV in the health sector; Geneva. (p 103)


38. Gari, S., Martin-Hilber, A., Malungo, J. R., Musheke, M., & Merten,
Noted, for example, in Turkmenistan (Chariyeva et al., 2011); China (Su et al., 2017); the UK (Hollingworth et al., 2016); and many other countries. Despite these differences, the overall trend is clear: middle- and high-income countries have lower rates of late presentation and ART initiation compared to lower-income countries.


Gender Considerations along the HIV Treatment Cascade: An Evidence Review with Priority Actions

...continued


The Evidence Project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of cooperative agreement no. AID-OAA-A-13-00087.

What Works for Women & Girls is supported by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and is being carried out under the auspices of the USAID-supported Evidence Project and What Works Association, Inc. For more information, please visit www.whatworksforwomen.org or email mcrocegalis@gmail.com.

The information provided in this document is not official U.S. Government information and does not necessarily represent the views or positions of the U.S. Agency for International Development.